Women differ from men in terms of their cardiovascular disease risk. The existing data suggest that primary cardiovascular disease prevention treatment with a statin could be cost effective for women and men with a high cardiovascular disease risk. In secondary cardiovascular disease prevention both men and women seem to benefit equally from statin treatment. However, the relatively small number of women included in several statin trials has limited the evidence available. With regard to the question of whether Eve is becoming Adam, the answer is not yet: we need more evidence!